The Notch pathway and the endocrine system constitute two key biological signaling mechanisms, responsible for cell-to-cell communication between adjacent cells and long-distance hormonal signals respectively. They play central roles during the development of higher eukaryotic organisms but they also take part in the regulation of many aspects of adult physiology and homeostasis. The contribution of defects in the normal transmission of hormone-dependent signals to the development of endocrine cancers has been widely analyzed and the knowledge derived from these studies has allowed us to develop many successful therapeutic strategies. However, in many cases these hormonal treatments become ineffective despite the fact that cancer cells maintain normal expression levels of wild-type hormone nuclear receptors. Less is known about the involvement of altered Notch signaling in the origin and progression of cancer, although there is clear evidence indicating that deregulation of Notch activity occurs in several types of tumors, including highly prevalent hormone-dependent types of cancer such as breast, ovarian and prostate cancer. This review will summarize accumulating data suggesting that Notch signaling plays a key role in the control of proliferation, differentiation and survival of prostate epithelial cells. Notch signals are required for normal prostate development and homeostasis, and abnormalities in Notch signaling may be critical during the development of prostate cancer. We will also discuss the possible oncogenic role for alterations in the crosstalk mechanisms between Notch and androgen-dependent signals during tumorigenesis in the prostate and how they could influence the outcome of anti-cancer hormonal treatments.
INTRODUCTION
The prostate is an exocrine gland of the male mammalian reproductive system, the primary function of which is to produce seminal fluids and it is also required for bladder control and normal sexual functioning. The development and homeostatic maintenance of the prostate are both regulated by an interplay between endocrine hormones, paracrine signals and local cell-cell interactions that modulate the specific genetic pathways controlling cell proliferation and differentiation (reviewed in [1] ). Alterations in these complex regulatory networks contribute to the abnormal cell physiology responsible for benign prostate hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and malignant prostate tumors [2] [3] [4] . Prostate cancer (PC) is the most frequently diagnosed neoplasm and the second leading cause of cancer-related death in men in western countries [5] , therefore much effort has been devoted to studying its etiology and to developing effective therapies against this disease. The prostate consists of glandular epithelium surrounded by fibromuscular stroma. Over 90% of prostate tumors arise within the glandular epithelial cell compartment [6] . For that reason, the elucidation of the molecular mechanisms that regulate epithelial cell proliferation and differentiation is an essential step towards understanding the basis of oncogenic transformation in the prostate gland. Among the endocrine hormones, androgens play a pivotal role in PC etiology because they are required for prostate epithelial cell growth and survival of both normal and malignant tissues [7, 8] .
Prostate epithelium is composed of two histologically distinct layers, a basal cell layer and a luminal secretory cell layer. There are at least three distinct major cell types in prostate epithelium [9] [10] [11] : basal cells, found underlying basal membrane; differentiated luminal cells that produce prostatic secretory proteins; and neuroendocrine cells scattered between the basal and luminal layers that secrete neuroendocrine peptides. The basal layer is the proliferative compartment of the prostate epithelium and there is a small subpopulation of basal cells that are thought to be true pluripotent stem cells [12] [13] [14] . These stem cells give rise initially to the so-called transit-amplifying cells that undergo further proliferation and differentiation to intermediate epithelial cells that will finally generate the terminally differentiated luminal secretory cells.
Responsiveness of normal and transformed prostate cells to androgenic stimulation is determined by the expression of the androgen receptor (AR), a member of the nuclear receptor (NR) superfamily of ligand-dependent transcription factors [15] .
Basal and transit-amplifying cells do not express androgen receptors and intermediate cells express AR protein at a very low level, however, all these cells require critical levels of androgen-stimulated paracrine growth factors for their proliferation but not for survival [11] . AR expression increases all along epithelial cell differentiation process reaching a maximum level in terminally differentiated luminal secretory cells. Luminal cells are non-proliferating but require constant androgen stimulation for survival [16] .
Thus, androgen signaling plays a pivotal role in the control of growth, function and proliferation of prostate epithelial cells. Androgens are not tumorigenic per se, but they are essential for the growth and perpetuation of tumor cells, hence androgensuppressing strategies have been widely used for the management of PC since the pioneering works of Huggings and Hodges in the early 1940s (reviewed in [17] ). The most common PC therapy is androgen elimination combined with antiandrogen treatment (termed maximal androgen blockade). However, most prostate tumors eventually become insensitive to this treatment and recur. The majority of such tumors continue to express AR but they are refractory to antiandrogen therapy. One of the fundamental challenges for researchers studying PC is understanding the pathways that lead to the transition to such so-called androgen independent prostate cancer (AIPC).
Several mechanisms have been proposed to explain the appearance of AIPC including mutations in AR, changes in the levels of AR and/or its coactivators and ligandindependent activation of AR through crosstalk with other signaling pathways (reviewed in [7, [18] [19] [20] ). Several major signaling pathways have been shown to affect AR function, such as growth factor receptor signaling, Mitogen activated protein kinase signaling (MAPK), cytokine signaling and Wnt signaling (reviewed in [21] ). In recent years accumulating evidence suggests that another major signaling pathway, Notch signaling, might be tightly intertwined with androgen signaling, contributing directly to the regulation of prostate gland development and function. In addition, several experimental observations indicate that aberrations in the expression of components of the Notch signaling pathway and/or alterations in the molecular mechanisms of crosstalk between Notch signals and AR may have a role in the origin and development of PC. The purpose of this review is to highlight these recent evidences linking Notch and AR regulatory axes and to discuss the possible role for Notch signaling as a potential PC therapeutic target.
NOTCH SIGNALING

Overview of the Notch signaling pathway
The Notch signaling pathway represents a major regulator of gene expression that plays a central role in cell fate decisions in metazoans, acting through local cell-cell interactions (reviewed in [22] ). Notch ligands and receptors are single-pass transmembrane proteins with large extracellular domains. Thomas Hunt Morgan first identified notch in 1917 and the gene was named after the notches that appear at the end of wing blades of fruit flies lacking a gene copy. Notch receptors and their ligands have since been identified in virtually all metazoans. In mammals there are four different Notch receptors (NOTCH1-4, [23] [24] [25] [26] [27] ) and five known Notch ligands named Deltalike1, -3 and -4 (DLL1, DLL3, DLL4, [28] [29] [30] ) and Jagged1 and Jagged2 (JAG1 and JAG2, [31, 32] ). The extracellular domains of all these proteins consist primarily of a variable number of epidermal growth factor (EGF)-like repeats responsible for the receptor-ligand interaction [33, 34] . The Notch signaling pathway is initiated when receptor-bearing cells interact with Notch ligands present on adjacent cells. This leads to two consecutive proteolytic cleavage events in the Notch receptor. The first cleavage is catalyzed by a member of the ADAM (A disintegrin and metalloprotease) family of metalloproteases and it sheds the extracellular portion of the Notch receptor [35] . This is followed by the action of gamma-secretase that hydrolyzes a peptide bond within the transmembrane domain releasing the Notch intracellular domain (NICD), which then translocates to the nucleus [36] . There, NICD binds to a transcriptional regulator known as CBF1/Su(H)/LAG-1 (CSL). In the absence of NICD, CSL inhibits expression of target genes by recruiting transcriptional corepressors such as NCoR, SHARP and CtBP [37, 38] . Interaction with NICD releases these corepressor complexes and allows the recruitment of transcriptional coactivators including MAML1 (mastermind-like 1) and histone acetyltransferases [39, 40] . The effects downstream of the NICD-CSL interaction are not completely understood, but the best characterized target genes directly activated by NICD-CSL are members of the bHLH-orange superfamily of transcriptional repressors [41] [42] [43] . Upon Notch activation the expression of several members of this family increases and they modulate cellular responses by suppressing expression of downstream target genes, constituting a transcriptional regulatory cascade. This is a simplified model of the so-called "classical" Notch pathway, although there is evidence for other less understood CSL independent signaling pathways triggered by Notch activation designated the "non-classical" pathway. It is beyond the scope of this review to describe in detail the complexities of the Notch pathway.
Notch function
Notch signaling is an evolutionarily conserved mechanism that participates in the development of multicellular organisms during embryonic and postnatal development. Notch signals in the regulation of other important cellular processes including apoptosis, migration, and adhesion, further reinforcing the biological relevance of this cell-cell communication mechanism [44, 45] .
It is noteworthy to mention that the Notch signaling cascade, although very simple in the basic core components responsible for the initiation of the signal, which are conserved through evolution, can be modulated by signal strength, timing, cell type and context. Therefore, Notch activation can have different or even opposing effects depending on the cellular context or its integration with other signaling pathways.
The role of Notch in carcinogenesis
Cancer comprises a group of diseases characterized by an abnormal development of cells proliferating in an uncontrolled way. The key role of Notch in the regulation of cell proliferation, differentiation and apoptosis make this pathway an obvious candidate to participate in the origin and/or progression of tumors when alterations in its normal function occur. The first evidence for an oncogenic role of Notch was identified in human T-cell acute lymphoblastic leukemia (T-ALL) [46] . The chromosomal translocation t(7;9) in human T-ALL results in deregulated expression of a truncated, constitutively active NOTCH1 receptor lacking most of its extracellular domain. Recent studies have shown that activating mutations of NOTCH1 are present in more than 50% of human T-ALLs [47] , supporting a critical role for NOTCH1 as an oncogene in this type of cancer (reviewed in [48] ). The expression of constitutively active NOTCH4 receptors also causes mammary tumors in mice [26, 49] and activated NOTCH1 signaling contributes to the neoplastic phenotype in human RAS-transformed cells [50] .
Although truncated forms of all four Notch receptors have transforming potential in vitro [51] and in animal models (reviewed in [52] [52] [53] [54] .
In keeping with the great context-dependency of the outcome of Notch activation, Notch signaling in tumorigenesis is not always associated with an oncogenic role induced by its aberrant stimulation. There is clear evidence demonstrating that Notch can also act as a tumor suppressor in certain types of cancers [52, 53] ), particularly skin cancer. In the epidermis, Notch signaling is required for keratinocyte growth arrest and entry into differentiation [55] . Moreover, conditional ablation of Notch1 in murine epidermis causes epidermal hyperplasia, skin tumors and facilitates chemical-induced skin carcinogenesis [56] , and transgenic mice expressing a dominant negative form of MAML1, a pan-Notch inhibitor, develop cutaneous squamous cell carcinomas [57] .
These observations indicate an antioncogenic role of Notch signaling in the epidermis.
Whether this tumor suppressor role of Notch signaling is extended to other tissues remains to be established.
NOTCH SIGNALING AND PROSTATE BIOLOGY
Notch signaling in prostate development
The first evidences indicating that Notch signaling may be involved in prostatic development came from experiments performed with rodent models by Gao and colleagues [58] . The previously documented relevance of cell-cell interactions in the regulation of proliferation, differentiation and tumorigenesis of prostate epithelial cells [6, [59] [60] [61] Further support for a central role of Notch signaling in the control of prostate epithelial biology came from recent work by John T. Isaacs and co-workers [64, 65] .
One of the fundamental constraints for PC research has been the lack of adequate in vitro human cell line models. Cells from prostate carcinomas have proven to be one of the most difficult cell types from which to establish cell lines. Seventeen human prostate carcinoma cell lines have been well-characterized [66] , but most in vitro studies have been performed using the three earliest established prostate carcinoma cell lines, which either contain a mutation in the AR gene that creates a promiscuous AR able to bind to and be activated by other steroids (LNCaP), or do not express AR (DU 145 and PC-3). These cell models have contributed significantly to our understanding of prostate cancer, but they cannot help us to elucidate the molecular pathways responsible for the development of PC at its early stages or to explain the causes of the AIPC phenotype observed in PC cells still expressing wild-type AR. In attempts to circumvent this problem, several groups have established new prostate cancer cell lines from human primary prostate tumors using low calcium (<300 µmol/L), serum-free, growth factordefined cell culture medium (that is in contrast to previously generated human PC cell lines that were originally established with and maintained in 10% fetal calf serum medium in which calcium is between 650 and 1,860 µmol/L). Under these culture conditions it was documented that from all non-transformed prostate epithelial cell populations, only transit-amplifying cells survive and these can be propagated for up to 10 serial passages [11, 63, 67] . To test whether in those cell culture conditions the nontransformed transit-amplifying cells derived from normal contaminating prostate epithelium were outgrowing cancer cells, Isaacs´ laboratory carried out a thorough characterization of prostate cell cultures derived from radical prostatectomy specimens [64] . As a result they observed that, in low calcium, serum-free, growth factor-defined medium, what grows are not truly prostatic cancer cells but basally derived normal transit-amplifying cells. One of the critical reasons that explains the selective outgrowth of the normal transit-amplifying versus cancer cells is the differential effect of lowcalcium conditions on the structure of NOTCH1 receptor. As discussed above, basal cells and early transit-amplifying cells express the receptor NOTCH1 and its ligand Jagged1. In low calcium medium, NOTCH1 receptor is conformationally in a constitutively active form allowing cell autonomous signaling independently of cell-cell interactions [68] . This ligand independent activation of Notch signaling contributes to the survival of transit-amplifying cells even in low cell density cultures. The addition of gamma-secretase inhibitors (GSIs) to prostate epithelial cell cultures, at concentrations that inhibit the production of the NICD transcription factor, was toxic, and there were no viable cells after 5 days of such treatment [64] . These results indicate that survival of prostate transit-amplifying cells requires unique NOTCH1 mediated signaling, strengthening the notion that Notch signals play an important role in the regulation prostate epithelial biology. Their results also suggest that transformed epithelial cells either do not express NOTCH1 receptor, or, because of the different cell-context, its activation is not sufficient to promote cell survival. At the 1 to 2 mmol/L physiological tissue calcium level, NOTCH1 signaling is not cell autonomous and it requires liganddependent activation. Under those conditions NOTCH1 signaling is no longer required for survival but instead contributes to stimulate proliferation of prostatic cancer cells.
The authors of this study suggest that these characteristics are consistent with the ability of PC to metastasize to bone, a tissue with high calcium levels.
Mechanisms of crosstalk between Notch and androgen signaling
More evidence for a possible direct role for Notch signaling in modulating prostate physiology derived from biochemical studies performed to characterize the molecular mechanism of action of NRs. AR belongs to the NR superfamily of liganddependent transcription factors. The ability of NRs to activate gene transcription depends on the recruitment of coactivator protein complexes with enzymatic activities that reorganize chromatin. Amongst the best characterized are the p160 family of coactivators, SRC1/NCoA1, TIF2/ NCoA2 and AIB1/NCoA3 [69] , which interact directly with ligand-bound NRs and serve as platform proteins recruiting both enzymes that catalyze posttranslational modifications [70] and ATP-dependent-chromatin remodeling complexes [71] . A yeast two-hybrid screen performed with the highly conserved bHLH-PAS N-terminal domain of SRC1 as bait identified a downstream target of Notch signaling, named HEY1 (hairy/Enhancer-of-split related with YRPW motif 1), as an SRC1-interacting protein [72] . Upon Notch activation, HEY1 expression is increased and it accumulates in the nuclei, acting as a transcriptional repressor of Notch target genes. Further functional characterization of this association demonstrated that HEY1 interacts directly with both SRC1 and the AR, and specifically represses transcription from AR-dependent promoters. Although SRC1 functions as a common coactivator for all NRs, HEY1 did not repress any of the other NRs tested. Another member of the HEY family that mediates Notch signaling, HEY2, was also able to specifically repress AR-dependent transcriptional activity. The mechanisms by which HEY1 and HEY2 repress AR, and the functional consequences of this interaction in vivo, remain to be elucidated. However, these in vitro experiments suggest that changes in endogenous levels of HEY1 in the cell, induced by Notch activation, have the potential to modulate cellular responses to testosterone, providing a molecular mechanism of coordination between long distance endocrine signals and cell-to-cell juxtacrine communication.
The negative feedback between androgen-dependent signals and Notch pathway may possibly occur in a reciprocal manner, based on recent gene profiling experiments described by Nantermet et al. [73] . To identify the androgen-responsive genetic pathways that regulate prostate cell division and differentiation they examined changes in global gene expression in the ventral prostate after DHT administration to androgendepleted rats. Among the transcripts expressed significantly differently they observed that AR stimulation repressed expression of Notch1 and its ligand Jagged1, also a negative regulator of Notch signaling, Sel11 [74] , was induced, indicating that DHT might inhibit Notch signaling. Their results, on one hand, reinforce the idea that Notch signals play a role in the regulation of prostate cell growth and proliferation, and, on the other, suggest that in vivo AR stimulation modulates Notch signaling in the prostate gland in a negative way. This study, along with the reported repression of AR activity by HEY1, a Notch target [72] , provides a mechanism for reciprocal negative feedback between androgen-dependent gene regulation and Notch. However, these large-scale gene expression analysis need to be validated by more experimental evidence and a detailed study of the prostate epithelial cell types involved in the crosstalk is lacking.
In light of recent results from Isaacs laboratory [65] , the direct role of HEY1 as an AR corepressor may in part explain the molecular mechanisms by which activated Notch signaling regulates prostate epithelial cell growth and differentiation. Continuing with their characterization of several nonimmortalized and immortalized human prostate epithelial cell lines and the consequences of maintaining them in low-calcium medium (i.e., subject to continuous, cell autonomous, activation of NOTCH1 receptor), they studied the effects of NOTCH1 signaling on differentiation of intermediate cells in
vitro. These cells fail to undergo full differentiation in vitro into mature, AR-expressing, luminal-secretory cells. Such inability is, at least in part, due to the continuous activation of NOTCH1 receptor that induces the expression of its downstream effector HEY1. HEY1 act as a transcriptional corepressor both for members of the family of GATA transcription factors [75, 76] and AR [72] . Thus, it has been proposed that HEY1 prevents the expression of GATA-and AR-regulated genes required for further differentiation of transit-amplifying cells into luminal-secretory cells. In agreement with this observation, human prostate cancer cell lines that are grown in high calcium containing medium do not express HEY1, which is consistent with their advanced luminal-secretory differentiation status [65] .
Mouse models
The critical role of Notch signaling in the control of prostate cell growth and differentiation suggested by the previously discussed studies, performed using in vitro models, has recently been confirmed by using animal models in ex vivo and in vivo In addition, they found that NOTCH1 mRNA expression was elevated in the prostate following castration but it returned to nearly normal levels after 3 days of hormone replacement, indicating that the proposed reciprocal negative feedback between Notch and androgen signaling [72, 73, 78] 
may indeed occur in vivo.
Subsequent studies from the same laboratory further exploited the ex-vivo prostate culture model to investigate how inactivation of Notch signaling affects the growth of rat neonatal prostate [79] . To do so, they used inhibitors of gamma-secretase, the enzyme responsible for the proteolytic step that leads to the generation of NICD. These 
NOTCH SIGNALING AND PROSTATE CANCER
All the experimental evidence described in the previous section indicates that Notch signaling plays a key role in the control of proliferation, differentiation and survival of prostate epithelial cells. Nearly all prostate adenocarcinomas originate within this prostate cell population; therefore it is predictable that alterations in the correct function of Notch signaling may contribute to the origin and progression of prostate cancer. Indeed, since the early studies linking the Notch pathway to prostate physiology, most laboratories working in the field have also characterized the expression of components of this pathway in established prostate cancer cell lines and human tumor samples, trying to correlate these data with effects on prostate cancer cell growth in vitro and in vivo. Below we will summarize the aforementioned studies.
The initial identification of Notch1 regulated expression during murine prostate development prompted Shou and colleagues to examine the expression of Notch1 in transgenic adenocarcinoma of the mouse TRAMP prostate cancer model [83] . These mice were generated by using the prostate luminal cell-specific rat probasin promoter to derive expression of the simian virus 40 large-tumor antigen coding region. Mice expressing the transgene display progressive forms of prostatic carcinomas with neuroendocrine features. In situ hybridization experiments showed that in TRAMP mice normal mature prostate Notch1 expression is either undetectable or very low, but malignant and metastatic prostate cells express high levels of Notch1 [58] . A parallel study of Jagged1 expression revealed that it was not detectable in the malignant epithelial cells in TRAMP tumors or in normal prostatic epithelium in wild-type mice, suggesting that in those tumor cells Notch signaling is not physiologically activated, or that its activation rely on different ligands or crosstalk with other signaling pathways. inhibited cell proliferation in all three prostate cancer cell lines [58] . Whether this reduction in the proliferation caused by NOTCH1 activation is due to an increase in the number of cells undergoing terminal differentiation and becoming mitotically inactive remain to be demonstrated. Another independent study showed that NOTCH1 and NOTCH2 mRNAs were expressed in prostate cancer cell lines (LNCaP, PC-3 and PC-3M) whereas NOTCH3 and NOTCH4 mRNAs were not detected [84] . The Notch ligands Jagged1, Jagged2 and DLL1 were expressed in all three prostate cancer cell lines, and their expression levels were significantly higher in those cell lines relative to the levels observed in normal prostate cells (PNT2 cell line).
Another study has shown that among human prostate cancer cell lines, those with osteomimetic properties express higher levels of Notch1 expression [85] . Prostate cancer metastasizes preferentially to the skeleton and elicits osteoblastic lesions by unknown mechanisms [86] , and it has recently been described that Notch signaling positively regulates osteoblastic cell differentiation [87] . Based on those evidences Zayzafoon and colleagues examined the role of Notch signaling during the development of osteomimetic properties of prostate cancer bone metastases [85] . They found that NOTCH1 expression is greatly increased (4-5 fold) in two osteoblastic skeletal prostate found that Jagged1 and Jagged2 expression were expressed at variable levels whereas DLL1 and DLL4 expression were negligible in all four cell lines. Downregulation of Jagged1 expression greatly decreased cell growth in those prostate cancer cell lines and NOTCH1 siRNA also induced growth inhibition, but to a lesser extent. These results add a new layer of complexity to the role of Notch in prostate cancer cells because the observed growth-inhibitory effects were independent of the cell line AR status, suggesting that Notch signaling impinges on androgen-independent cell growth regulatory mechanisms, in addition to its proposed role as a regulator of AR function.
More in depth analysis of the mechanisms underlying cell growth inhibition in PC-3 cells depleted of endogenous Jagged1 or NOTCH1 showed that both Jagged1 and NOTCH1 siRNA induced S-phase arrest. In the case of Jagged1 knockdown, S-phase arrest was associated with reduced CDK2 kinase activity and increased expression of the cyclin-dependent kinase inhibitor p27(Kip1), suggesting that one of the mechanisms by which Notch signaling controls cell cycle is through regulation of CDK2 activity.
The downregulation of CDK2 levels and the increase of p27 expression induced by Jagged1 siRNA treatment occur mainly at protein level and further studies will be required to uncover the detailed cellular pathways modulated by Notch responsible for these effects. The stronger growth inhibitory effects of Jagged1 knockdown compared to NOTCH1 knockdown suggest that Jagged1 itself could be important in prostate cancer cell growth independent of its role as a Notch ligand.
Belandia et al. [72] Meta-analysis of microarray datasets including tumors, as well as respective normal control tissue samples, has revealed that NOTCH1 gene and one of the downstream target genes, HEY1, are down-regulated significantly in prostate adenocarcinomas [79] . The expression levels of NOTCH1 in 51 prostate tumors were significantly lower than normal prostate samples and the mean level of HEY1 expression was also significantly lower in 93 prostate adenocarcinomas than both normal and tumor-adjacent normal tissues. These observations reinforce the idea that NOTCH1 and HEY1 may be important in prostate tumorigenesis.
Finally, additional evidence for dysregulation of Notch1 expression in prostate cancer was revealed by expression analysis performed during prostate tumor development in the LADY transgenic mouse model [92] . These mice express the large T antigen gene, containing a deletion mutation that removes expression of small t antigen, under the control of the prostate luminal cell-specific rat probasin promoter [93] . As compared with the TRAMP mouse model, tumor progression is less aggressive in LADY transgenic mice, but they develop multifocal low-grade PIN that progresses to high-grade PIN and early invasive carcinoma with neuroendocrine characteristics but no metastasis. NOTCH1 expression increased significantly in the six-week developing tumor, but not in the established 16-week tumor [92] . These observations suggest that NOTCH1 has an early role in the regulation of prostate epithelial cell proliferation and differentiation prior to the appearance of histological changes. Increased NOTCH1 expression was also found in prostate tumors from TRAMP mouse models [58] .
However, in this model of prostate carcinogenesis, high NOTCH1 expression is maintained even in metastasized tumor cells. This discrepancy between both models may reflect the different mechanisms responsible for the oncogenic development and/or differences in the strain background between the TRAMP and the LADY models. In addition, conversely to the up-regulation of Notch1 expression observed in these SV40 oncogene-derived mouse models of prostate carcinogenesis, the meta-analysis of human prostate adenocarcinoma mentioned above found downregulation of NOTCH1 expression in human cancer samples [79] . We do not know yet whether these apparently Overexpression of a constitutively active form of NOTCH1 inhibited the proliferation of various prostate cancer cells, including DU 145, LNCaP and PC-3 cell lines [58] . In contrast, siRNA-mediated downregulation of NOTCH1 or Jagged1 also induces cell growth inhibition and S phase arrest in the same prostate cancer cell lines [91] , and in vitro studies with GSIs demonstrated that reduction of Notch signaling induces a moderate inhibition of proliferation in LNCaP and DU-145 cells [64] . Even though all these studies point to an important role for Notch signaling in the regulation of prostate cancer cell proliferation, the complexity of the biological role of Notch signals in the prostate cell make it difficult to decipher whether Notch acts an oncogen or a tumor suppressor. In addition, these effects occur both in AR dependent and AR-independent prostate cancer cell lines, suggesting that besides the previously described crosstalk between AR-dependent and Notch signals, Notch also regulates prostate cells by means of crosstalk with androgen-independent transduction pathways. [52] ). Currently, the most advanced strategy for blocking Notch signaling is to suppress the proteolytic step that leads to the release of the activated intracellular domain of Notch receptors [81] . This step is catalyzed by the gammasecretase, a large integral membrane protease complex composed of a catalytic subunit (presenilin-1 or presenilin-2) and three accessory subunits (Pen-2, Aph1 and nicastrin [36, 95, 96] ). This enzyme is also responsible for the proteolytic step that releases the amyloid β-peptide, the precursor of amyloid plaques found in the brain of Alzheimer´s disease. For that reason, over the past years, a great variety of small molecules of pharmaceutical utility have been designed, and already tested in animal models and clinical trials, able to inhibit gamma-secretase activity. This preceding research has speeded up the initiation of phase 1 clinical trials designed to evaluate the effectiveness of one GSI (MK-0752) for the treatment of T-ALL 1 (Fig. (1) 
